[Show abstract] [Hide abstract]
ABSTRACT: Abstract Epidemiological studies have evaluated the associations between brain-derived neurotrophic factor (BDNF) 196A/G gene polymorphism and Alzheimer's disease (AD) risk. However, the results remain inconclusive. Sexually dimorphic effect of the polymorphism of BDNF 196A/G in AD patients had been proposed previously, specifically in female group. With more cases reported, therefore, we perform a meta-analysis of published case-control studies to better understand these results. We systematically searched online databases of Embase, PubMed and Web of Science, as well as hand searching of the references of identified articles and meeting abstracts. Review Manager (Version 5.2.4) and Stata software (Version 12.0) were used for statistical analyses. The pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. A total of 23 publications including 25 studies were identified and entered the analysis. No significant association was observed in overall population, as well as subgroups stratified by ethnicity (Caucasian and Asian). However, when stratified by gender, significant association was observed just in female subgroup (A allele vs. G allele: OR = 1.15, 95% CI = 1.06-1.25; A/A vs. G/G: OR = 1.29, 95% CI = 1.06-1.57; A/A + A/G vs. G/G: OR = 1.30, 95% CI = 1.11-1.53). This meta-analysis confirmed the gender-related association between BDNF 196A/G polymorphism and AD risk, which may indicate a certain effect of female hormone on progression of the disease. Larger sample size and more studies with homogeneous AD patients and well-matched controls are needed in future.
The International journal of neuroscience 11/2013; · 1.53 Impact Factor
After the Kidney Transplant - The Patients and Their Allograft, 08/2011; , ISBN: 978-953-307-807-6
[Show abstract] [Hide abstract]
ABSTRACT: Insomnia, defined as difficulty in falling asleep and/or staying asleep, short sleep duration, or poor quality sleep, is a common sleep disorder affecting 30-40% of adult population. We have conducted a randomized, double-blind, placebo-controlled study to test if anesthesia is therapeutically beneficial in patients with refractory chronic primary insomnia. We have assessed the efficacy and safety of propofol-induced sleep in these patients. This study comprised of 103 patients with refractory chronic primary insomnia (including 59 non-pregnant, non-lactating women; 28-60 years) and the participants were randomized to receive either physiological saline (placebo) (n = 39) or 3.0 g/l propofol (n = 64) in a 2-h continuous intravenous infusion for five consecutive nights. The Leeds Sleep Evaluation Questionnaire was used for the subjective assessment of sleep, and polysomnography was used for the objective measurement of sleep architecture and patterns. The assessments were done prior to and at the end of the 5-day treatment and 6 months after treatment period. The adverse effects of the treatment were also recorded. A 2-h continuous intravenous infusion of 3.0 g/l propofol for five consecutive nights improved the subjective and objective assessments of sleep in 64 patients with refractory chronic primary insomnia. This improvement occurred immediately after the therapy and persisted for 6 months. No serious adverse events were noticed during the period of drug administration or 6 months after the treatment. Propofol therapy is an efficacious and safe choice for restoring normal sleep in patients with refractory chronic primary insomnia.
Cell biochemistry and biophysics 11/2010; 60(3):161-6. · 3.34 Impact Factor